Cargando…
CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
BACKGROUND: Chimeric antigen receptor NK (CAR-NK) cell therapy is one of the most promising immunotherapies. Although it has shown a significant therapeutic effect in hematologic malignancies, few successes have been obtained in solid tumors including esophageal squamous cell carcinoma (ESCC). The m...
Autores principales: | Liu, Tingdang, Dai, Ximing, Xu, Yien, Guan, Tian, Hong, Liangli, Zaib, Tahir, Zhou, Qi, Cheng, Ke, Zhou, Xiaoling, Ma, Changchun, Sun, Pingnan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563326/ https://www.ncbi.nlm.nih.gov/pubmed/37817249 http://dx.doi.org/10.1186/s12967-023-04409-8 |
Ejemplares similares
-
Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy
por: Zaib, Tahir, et al.
Publicado: (2023) -
Evaluation of multiple immune cells and patient outcomes in esophageal squamous cell carcinoma
por: Wang, Hui, et al.
Publicado: (2023) -
Recent Advances in Syndactyly: Basis, Current Status and Future Perspectives
por: Zaib, Tahir, et al.
Publicado: (2022) -
Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023) -
Direct Differentiation of Human Embryonic Stem Cells to 3D Functional Hepatocyte-like Cells in Alginate Microencapsulation Sphere
por: Xie, Xiaoling, et al.
Publicado: (2022)